TLX Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$1,664,163.00
Insider Selling (Last 12 Months): A$15,400,000.00

Telix Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Telix Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Telix Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/12/2020 01:00 AM ET

This chart shows the closing price history over time for TLX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Telix Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/3/2022Tiffany OlsonInsiderBuy33,000A$4.11A$135,663.00
4/27/2022Oliver BuckInsiderBuy250,000A$4.37A$1,092,500.00
2/3/2022Christian BehrenbruchInsiderBuy400,000A$1.09A$436,000.00
1/27/2022Christian BehrenbruchInsiderSell2,000,000A$7.70A$15,400,000.00
9/29/2021Harry McCannInsiderBuy990,000A$0.85A$841,500.00
5/12/2021Christian BehrenbruchInsiderIssued100,708A$3.71A$373,626.68
11/2/2020Oliver BuckInsiderBuy165,330A$0.85A$140,530.50
5/12/2020Christian BehrenbruchInsiderIssued200,000A$1.47A$294,000.00
2/13/2020Oliver BuckInsiderBuy164,835A$0.85A$140,109.75
See Full Table

SEC Filings (Institutional Ownership Changes) for Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals logo
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Read More on Telix Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

746,789 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Telix Pharmaceuticals?

Telix Pharmaceuticals' top insider shareholders include:
  1. Christian Behrenbruch (Insider)
  2. Harry McCann (Insider)
  3. Oliver Buck (Insider)
  4. Tiffany Olson (Insider)
Learn More about top insider investors at Telix Pharmaceuticals.